Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2025

Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes. Treatment approaches vary by subtype, but rituximab in combination with chemotherapy remains the mainstay of treatment across NHL subtypes. Recent label expansions are giving hematologist-oncologists an ever-increasing array of treatment options, including Epkinly (Genmab / AbbVie) and Brukinsa (BeiGene) for relapsed/refractory (R/R) follicular lymphoma (FL) and Breyanzi (Bristol Myers Squibb) for R/R CLL, R/R FL, and R/R mantle-cell lymphoma (MCL). These advances, alongside shifting prescribing patterns and increasing competition, are reshaping the treatment of NHL and CLL.

Questions answered

• What are the uptake and patient share of key therapies and regimens across all NHL / CLL subtypes, according to surveyed hematologist-oncologists?
• How does physician prescribing of current treatments vary based on genetic mutations and CAR T-cell- and transplant-eligibility criteria?
• How do drug-treatment rates vary across key B-cell NHL / CLL subtypes by line of therapy?
• What are the key drivers and obstacles determining current prescribing patterns in NHL / CLL?
• What are the clinical characteristics that physicians consider when prescribing CAR T-cell therapies and bispecific antibodies for the various NHL / CLL subtypes?

Primary research: Survey of 100 hematologist-oncologists in the United States fielded in December 2024

Key drugs covered: Breyanzi, Brukinsa, Calquence, Columvi, Epkinly, Imbruvica, Jaypirca, Kymriah, Lunsumio, rituximab, Tecartus, Venclexta, Yescarta

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.